Gadolinium deposition disease lawsuit Claims & Settlements

Gadolinium Contrast Dye MRI Lawsuit for deposition disease poisoning

The lawyers and attorneys at National Injury Help are now accepting cases of gadolinium deposition disease (GDD) poisoning.  MRI dyes currently used in enhanced MRI exams have been linked to a condition called deposition disease.

The basis of these new gadolinium lawsuits is the failure of the manufactures to warn about the possible health risks. There may be substantial cash awards from claims and settlements in these cases.

It was previously thought in the medical community that Gadolinium Deposition Disease is uncommon, however recent studies show this may not be the case. Gadolinium-related diagnosis for patients with normal renal function did not exist up until recently.

What is Gadolinium Deposition Disease or Gadolinium Storage Condition?

Gadolinium is a whitish rare earth metal discovered in 1880 by Jean Charles de Marignac. It has, by nature fluorescent properties.  It’s these properties that are sought after for use in the medical world, mostly for the use in magnetic resonance imaging.  Many currently used MRI contrast agents in America contain some level of gadolinium.  Generally speaking most of the time gadolinium use over the years has proved safe in MRIs.

To answer the question of what is gadolinium deposition disease, (also called Gadolinium Storage Condition) we pulled current information from the Radiological Society of North America for some answers.Mayo Clinic Gadolinium Deposition Disease

New research from the Mayo Clinic has found the potential for gadolinium residue to remain in the brains of people who have undergone multiple contrast-enhanced MRI exams. 

According to Emanuel Kanal, M.D., director of magnetic resonance services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center.

“We now have clear evidence that the administration of various gadolinium-based contrast agents results in notably varied levels of accumulation of residual gadolinium in the brain”.

“Integral to the safety of gadolinium contrast agents is the persistence of the gadolinium-chelate bond for as long as the agent remains within the patient”.

Near the end of the published article he does mentions some words of encouragement for those facing MRI scans. “Gadolinium-based contrast agents are extremely valuable to patients worldwide and have been so for decades, we cannot unnecessarily deprive our patients of crucial, even life-saving medical data from gadolinium contrast-enhanced MRI. Nor can we ignore these new findings and continue prescribing them as we have until now, without change.”

The study published in the journal Radiology, strongly suggests that some types of contrast dyes used in magnetic resonance imaging (MRI) exams may in fact remain in the brain for years. Though long term effects of this gadolinium residue is not fully understood.

 What are the symptoms of gadolinium deposition disease (GDD)?

The Journal of Practical Medical Imaging and Management has a good overview of gadolinium deposition disease. They mention an article in Magnetic Resonance Imaging that states the following:

“In their article, the authors focus on GDD, a condition in which patients with normal renal function develop a variety of symptoms. European-origin Caucasian women more are more susceptible to developing GDD. The authors believe that patients with GDD develop an immunologic response that is dependent on the genetic susceptibility of an individual. Symptoms include bone pane, skin and subcutaneous tissue burning pain, and various intensities of what is described as “chemo brain” or “brain fog.Progressive thickening and discoloration of the skin and subcutaneous tissue of the distal arms and legs can occur in late stage disease.Brain with Gadolinium Deposition Disease

Symptoms of GDD occur within hours to days of gadolinium-based contrast agent administration. The authors believe that GDD may be a blend of a polypeptide-mediated response with a cell-mediated subacute adverse event. They suggest that a patient with GDD may have a genetic abnormality in metabolizing heavy metals.

The most reliable laboratory test to confirm gadolinium deposition may be a 24-hour urine test, according to the authors. They believe that the 24-hour urine gadolinium provides the best window for “mobile” circulating gadolinium in the patient, whereas a blood sample only provides a snapshot view.”

What are the brands of Gadolinium Contrast Dyes?

All of the following brands of contrast dyes contain some level or formulation of gadolinium.

  • Ablavar (gadofosveset trisodium)
  • Dotarem (gadoterate meglumine)
  • Eovist (gadoxetate disodium)
  • Gadavist (gadobutrol)
  • Magnevist (gadopentetate dimeglumine)
  • MultiHance (gadobenate dimeglumine)
  • Omniscan (gadodiamide)
  • OptiMARK (gadoversetamide)
  • ProHance (gadoteridol)

New FDA Warning for Gadolinium

The FDA has published a new MedWatch Alert. Here is the actual warning:

Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication – Retained in Body; New Class Warnings.FDA warning Gadolinium Deposition Disease

AUDIENCE: Radiology, Health Care Professional, Patient

ISSUE: FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.

However, after additional review and consultation with the Medical Imaging Drugs Advisory Committee, FDA is requiring several actions to alert health care professionals and patients about gadolinium retention after an MRI using a GBCA, and actions that can help minimize problems. These include requiring a new patient Medication Guide, providing educational information that every patient will be asked to read before receiving a GBCA. FDA is also requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.

To date, the only known adverse health effect related to gadolinium retention is a rare condition called nephrogenic systemic fibrosis (NSF) that occurs in a small subgroup of patients with pre-existing kidney failure. FDA received reports of adverse events involving multiple organ systems in patients with normal kidney function. A causal association between these adverse events and gadolinium retention could not be established.

BACKGROUND: This is an update to the May 22, 2017 MedWatch safety alert “Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication – No Harmful Effects Identified With Brain Retention“.

GBCAs are used with medical imaging devices called MRI scanners to examine the body for problems such as cancer, infections, or bleeding. GBCAs contain gadolinium, a heavy metal. These contrast agents are injected into a vein to improve visualization of internal organs, blood vessels, and tissues during an MRI, which helps health care professionals diagnose medical conditions. After being administered, GBCAs are mostly eliminated from the body through the kidneys. However, trace amounts of gadolinium may stay in the body long-term. Many GBCAs have been on the market for more than a decade.

There are two types of GBCAs based on their chemical structures: linear and macrocyclic (see Table 1 in Drug Safety Communication). Linear GBCAs result in more retention and retention for a longer time than macrocyclic GBCAs. Gadolinium levels remaining in the body are higher after administration of Omniscan (gadodiamide) or OptiMARK (gadoversetamide) than after Eovist (gadoxetate disodium), Magnevist (gadopentetate dimeglumine), or MultiHance (gadobenate dimeglumine). Gadolinium levels in the body are lowest after administration of Dotarem (gadoterate meglumine), Gadavist (gadobutrol), and ProHance (gadoteridol); the gadolinium levels are also similar across these agents.

RECOMMENDATION: Health care professionals should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention (see Table 1 listing GBCAs). These patients include those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies. However, do not avoid or defer necessary GBCA MRI scans.

Patients, parents, and caregivers should carefully read the new patient Medication Guide that will be given to you before receiving a GBCA. The Medication Guide explains the risks associated with GBCAs. Also tell your health care professional about all your medical conditions, including:

  • If you are pregnant or think you might be pregnant
  • The date of your last MRI with gadolinium and if you have had repeat scans with gadolinium
  • If you have kidney problems

————————————END OF FDA GADOLINIUM WARNING————————————

Gadolinium lawsuit brought by Chuck Norris – says MRI chemical poisoned wife.

A story made news headlines on November 2, 2017 when Chuck Norris and his wife filed a gadolinium lawsuit. In this lawsuit they claim that an MRI containing gadolinium poisoned his wife and left her with burning pain. The lawsuit was filed in San Francisco. Read more here from CBS News:

Past Gadolinium Lawsuits for Nephrogenic Systemic Fibrosis (NSF)

It was back in 2005 when law firms across the U.S. began looking at the problems of gadolinium use in MRIs.

In one case the plaintiff, Paul Decker, had an MRI and was given a dose of commonly used gadolinium called Omniscan. During that procedure Mr. Decker was also suffering from kidney failure. It was alleged that this triggered the condition known as Nephrogenic Systemic Fibrosis (NSF).   The Sixth Circuit of the U.S. Court of Appeals affirmed a $5,000,000 dollar award to him.

Do I qualify to file a Gadolinium deposition disease lawsuit?

Brain fog gadolinium deposition disease

Patient with “Brain fog or Chemo Brain” from gadolinium deposition disease (GDD)

Our gadolinium lawyers and attorneys are here to help if you or someone you love has had any side effects from any gadolinium MRI contrast dye including:

  • Brain fog or “chemo brain” symptoms.
  • Memory loss.
  • Impairment in thinking.
  • Intense burning of the skin
  • Intense bone or joint pain.
  • Discoloration in the lower arm or leg.
  • Skin thickening.
  • Skin stiffness.

Feel free to call us directly at 1-800-214-1010 or use the contact form below, it costs nothing and you could receive a substantial cash award for your pain and suffering.

Gadolinium compensation amounts – Common questions on Gadolinium lawsuits

  • How much can you get from a gadolinium lawsuit?
  • I got brain fog or burning skin from gadolinium, can I sue?
  • How much compensation would I get from a gadolinium lawsuit?
  • How much are the settlement amounts in the gadolinium lawsuits?

The answer to these questions can be difficult to predict, as the gadolinium class action or MDL for this hasn’t started yet. There is still time for join in this gadolinium lawsuit, but there are statutes of limitations that apply. As you can see above one verdict in 2005 netted $5,000,000.

Some of the past defective drug lawsuits have had millions of dollars in a compensation fund, and then that is divided up between all who have joined the lawsuit. Example: $50,000,000 in a settlement fund that would serve 1,000 victims would be $50,000 per person. This is only an example and does not represent what may happen for gadolinium.


Gadolinium Support Groups Online.

While scanning the internet for information for this page, we found a Yahoo group that specializes on gadolinium toxicity. Here is the link:



Gadolinium Deposition Disease Lawsuit Claims & Settlements | Contrast Dye MRI page updated on June 10, 2019.